Author: Vivian Xie 22nd July 2026

Since it was passed into law in 2022, the Inflation Reduction Act (IRA) has forced the pharma industry to confront its most significant pricing policy transformation in decades. The first round of drugs to be released under this model were announced in summer 2023, and their negotiated prices came into effect at the start of 2026. Current pharmaceutical pricing strategies reflect their impact, with products seeing price reductions between 38% and 79% [1] compared to list prices.

The IRA’s impact also extends to all facets of drug price negotiations, from portfolio investment decisions and lifecycle management strategies to manufacturing cost optimisation initiatives. This marks a departure from the United States' historical approach to pharmaceutical pricing, which prohibited direct pricing negotiations with manufacturers under Medicare Part D and Part B programmes. The new framework gives the Centers for Medicare & Medicaid Services (CMS) authority to negotiate prices for select high-expenditure drugs which do not have generic or biosimilar competition, to a total of 30 Part D and Part B drugs [2] by 2029.

Pharmaceutical manufacturers face substantial penalties (namely, excise taxes at a starting rate of 65% of product sales, potentially escalating to 95%) if they refuse to come to the table for negotiations. This effectively forces them to participate, despite the act’s so-called voluntary status, and fundamentally alters the risk-return calculus for pharmaceutical investment, particularly for products targeting chronic conditions in elderly populations where Medicare represents the dominant payer.

For European pharmaceutical companies with substantial commercial exposure in the US, IRA pricing provisions pose new challenges, as impacted products are often those which generate disproportionate revenues in American markets compared with their domestic counterparts. With global pharma markets more interconnected than ever, any changes in pricing policy will have inevitable reverberations across the industry. Here’s what you need to understand in order to manage your portfolios successfully in this time of sector-wide change.

The Magnitude and Mechanics of Negotiated Price Reductions

The first cohort of IRA-negotiated drugs was announced in August 2023, representing approximately USD 50 billion in annual Medicare spending; this was made up of 10 drugs, including widely prescribed medications for diabetes, cardiovascular disease and autoimmune conditions. The aforementioned reductions of up to 79% substantially exceed any previous discounts or rebates that pharmaceutical manufacturers historically offered under existing Medicare plans, representing genuine margin compression at an unprecedented scale.

The CMS negotiation framework incorporates multiple factors in determining maximum fair prices, including manufacturer-specific data on research and development costs and federal financial support received during development, production and distribution. The framework also considers the extent to which a drug represents therapeutic advancement and addresses unmet medical needs, incentivising pharmaceutical companies to document their products’ innovation value and clinical differentiation. This puts constraints on newer products, with those who have met FDA approval more recently facing a ceiling price closer to 75% [3] than the initial 40% for patents which are nearer to expiry.

The selection criteria prioritises high-expenditure products that have been on the market for at least nine years for small molecule drugs and thirteen years for biologics, without facing generic or biosimilar competition. This approach puts blockbuster products in their mature lifecycle stages at the greatest likelihood of exposure to negotiations, while newer products and those facing imminent loss of exclusivity will only be granted temporary protection. The number of negotiated drugs continues to grow each year, which means that the current phased implementation schedule creates ongoing uncertainty for pharmaceutical companies, who have no idea which products will be up for negotiation in future cycles. This complicates their long-term commercial forecasting and ability to value their portfolios accurately.

Optimising Portfolios in Response to Pricing Pressures

Pharmaceutical companies are putting comprehensive portfolio optimisation strategies into place to reassess their investment priorities, accelerate lifecycle management initiatives and reallocate resources toward less vulnerable therapeutic areas. This increasingly favours products with smaller patient populations, shorter treatment times and any clearly-sustained clinical differentiation. By comparison, treatments addressing chronic conditions (once the most commercially attractive pharma products) are seeing reduced investment due to their being at greater risk of scrutiny [4] under the IRA negotiation framework.

Lifecycle management strategies have also intensified as pharmaceutical companies seek  out new formulations, delivery systems and indication expansions as a way to extend product differentiation and delay IRA negotiation eligibility. These development require substantial investment in formulation science, clinical trials and regulatory submissions, and their success depends on demonstrating sufficient clinical value to justify separate regulatory approval and payer coverage, as opposed to an incremental modification of existing products.

Imperatives for Optimising Manufacturing and Operational Costs

Negotiating price reductions creates intensified imperatives for pharmaceutical companies to optimise their output wherever possible to offset declining revenues and compressed margins. More and more, pharma pricing compliance strategies [5] incorporate initiatives to reduce manufacturing costs; these encompass process improvements to reduce material consumption or cycle times, technology investments that enhance yields or throughput and strategic sourcing initiatives that secure more favourable pricing for raw materials and components.

Continuous manufacturing represents a particularly attractive area of investment, typically delivering 30–50% reductions in manufacturing costs compared to traditional batch processing. The business case for continuous manufacturing is actually bolstered by revenue compression, where incremental improvements in efficiency become economically material  results. What’s more, the investment required to implement these processes can be easily justified through by the long-term savings they will bring in.

Contract manufacturing and outsourcing strategies have also received renewed attention, as pharmaceutical companies evaluate the economic viability of outsourcing some of their processes through specialised contract development and manufacturing organisations (CDMOs). For products facing negotiated price reductions that compress margins to levels where internal manufacturing becomes economically marginal, outsourcing to lower-cost CDMOs may represent the difference between continued commercial viability and product discontinuation.

The Regulatory and Policy Considerations Driving Pharma’s Response

Pharma pricing compliance strategies must navigate multiple regulatory considerations including the IRA's statutory requirements, CMS implementation guidance, Federal Trade Commission oversight of competitive practices and Securities and Exchange Commission disclosure obligations regarding material business impacts. The IRA's inflation rebate provisions require manufacturers to pay Medicare if drug prices increase faster than inflation, further constraining pricing flexibility and compounding margin pressures.

Products subject to both negotiated prices and inflation rebates face dual pricing constraints that limit manufacturers' ability to offset lost Medicare revenue through price increases in commercial markets. The effectively caps their annual price increases for all products covered by Medicare Part B and Part D at the consumer price index, fundamentally altering pricing dynamics that have historically been substantially higher than general inflation on a yearly basis. The international implications of these pricing policy changes create additional complexity for multinational pharmaceutical companies, as the United States provides a key benchmark for many countries’ reference pricing systems. Any negotiated Medicare prices which fall substantially below historical US levels may have a knock-on effect for countries that rely on reference pricing; the resulting impact on global revenues would far exceed the direct losses otherwise made through Medicare.

How Pharma Can Leverage Innovation Platforms to Adapt to New Market Realities

With a focus on advanced analytics and artificial intelligence, the pharma sector is putting substantial investment into tech to enable more sophisticated approaches to portfolio optimisation. Through virtual modelling of negotiation risk scenarios and revenue trajectory forecasting, these analytical capabilities help to support decision-making by balancing commercial potential against negotiation exposure and incorporate probability assessments of future policy developments.

Digital health integration and companion diagnostic development are two emerging differentiation strategies with the potential to support premium pricing or reduce vulnerability in negotiations through demonstrated clinical and economic benefits. Integrated solutions which can enable personalised dosing or identify optimal patient populations have the potential to command different pricing dynamics from standalone pharmaceutical products. The regulatory pathways and reimbursement frameworks for these integrated solutions are still evolving, offering a viable (if untested) path for pharmaceutical companies looking to use tech to their advantage.

Furthermore, industry events like CPHI Milan, taking place 6-8 October 2026, are ideally placed to connect international pharmaceutical companies, technology providers and service organisations. The show’s concentration of pharmaceutical industry stakeholders enables networking and relationship development to support the cross-functional collaboration required to implement comprehensive adaptation strategies. And with zones dedicated to Integrated Pharma, Contract Manufacturing and AI & Tech (among many others), the show is designed to address the uncertainties brought about by the IRA head-on. For pharmaceutical companies implementing portfolio optimisation strategies, lifecycle management initiatives, or manufacturing cost reduction programmes, this is a valuable forum for technological discovery, vendor evaluation and knowledge exchange that can inform strategic decisions and implementation approaches for years to come.